Classic psychedelics, including psilocybin, LSD, DMT, 5-MeO-DMT, mescaline, and phenethylamines such as DOI, exert their core effects through 5-HT2A receptor agonism, inducing widespread neurobiological and behavioral changes relevant to psychiatric research. Emerging evidence suggests that these effects are modulated by sex, yet this dimension remains underrepresented in studies. This review...
Frontiers in PsychiatryJune 10, 2026Justyna Śniadach, Sylwia Szymkowiak, Przemysław Osip et al.
Background: Cannabis use has increased across Europe over the last decade, accompanied by growing availability of high-potency THC products and rising psychiatric presentations. Despite these trends, European countries differ substantially in monitoring systems, clinical preparedness and public health responses. These disparities are especially visible between Western Europe, which has more...
This review is limited by the heterogeneity in reporting side effects and the short duration of many studies. Future studies should transparently and systematically present a description of side effects.
Anxiety disorders significantly reduce patients' quality of life. Current pharmacological treatments, primarily benzodiazepines and antidepressants, are associated with numerous side effects. Consequently, there is a continual search for alternative methods to traditional therapies that are less burdensome for patients and broaden their therapeutic options. Our objective was to determine the...
PsychiatriaJune 5, 2024Anna Stankiewicz, Jan Szewczyk, Julia Truszkowska et al.1 citation
Drug therapies for many psychiatric conditions do not meet patients’ expectations. New agents are being sought to treat depression and anxiety disorders, among others. Scientific interest in psychoactive substances has increased over the past few decades. Recent studies provide evidence that psychedelics may find use in the treatment of a range of mental disorders. This paper describes new...